QIAGEN NV (QGEN)

34.56
0.24 0.69
NYSE : Health Technology
Prev Close 34.80
Open 34.98
Day Low/High 34.56 / 35.11
52 Wk Low/High 32.33 / 41.55
Volume 1.07M
Avg Volume 893.40K
Exchange NYSE
Shares Outstanding 226.97M
Market Cap 7.76B
EPS 0.80
P/E Ratio 41.67
Div & Yield N.A. (N.A)

Latest News

QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed And Interpreted

QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed And Interpreted

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QIAGEN Clinical Insight (QCI®), its clinical decision support platform for interpretation and reporting of variants derived from analysis of next-generation sequencing (NGS) data, has...

QIAGEN And McKesson Agree To Distribute QIAstat-Dx Syndromic Testing Solution To Smaller Hospitals And Other Select Segments In The United States

QIAGEN And McKesson Agree To Distribute QIAstat-Dx Syndromic Testing Solution To Smaller Hospitals And Other Select Segments In The United States

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) today announced an agreement for McKesson Medical-Surgical Inc.

QIAGEN To Deliver Genomic Insights For Japan's New Molecular Oncology Clinical Research And Precision Medicine Initiative

QIAGEN To Deliver Genomic Insights For Japan's New Molecular Oncology Clinical Research And Precision Medicine Initiative

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insight (QCI) offering was selected by the National Cancer Center of Japan, as part of the Japan's Ministry of Health, Labour and Welfare's precision medicine...

QIAGEN And DiaSorin Collaborate On Novel QuantiFERON-based Test With Breakthrough Potential For Earlier Detection Of Lyme Disease

QIAGEN And DiaSorin Collaborate On Novel QuantiFERON-based Test With Breakthrough Potential For Earlier Detection Of Lyme Disease

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is expected to address a significant...

QIAGEN Launches First FDA-approved Companion Diagnostic For PIK3CA Biomarkers To Enhance Precision Medicine In Breast Cancer

QIAGEN Launches First FDA-approved Companion Diagnostic For PIK3CA Biomarkers To Enhance Precision Medicine In Breast Cancer

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the immediate launch of its therascreen ® PIK3CA RGQ PCR Kit ( therascreen PIK3CA Kit) after it received U.

Inovio And QIAGEN Establish Collaboration To Develop Diagnostic Test For VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Inovio And QIAGEN Establish Collaboration To Develop Diagnostic Test For VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio's VGX-3100

QIAGEN Posts 2018 Annual Report On Its Website

QIAGEN Posts 2018 Annual Report On Its Website

QIAGEN N.V.

QIAGEN N.V. To Report First Quarter 2019 Results

QIAGEN N.V. To Report First Quarter 2019 Results

QIAGEN N.V.

TheStreet Quant Rating: B (Buy)